Antibacterial Agents TRIZ Cases

Combining cholesterol with CpG oligonucleotides creates a composite adjuvant that boosts cytokine secretion and antibody production.

Dual crosslinked PVA linseed hydrogel patches inhibit Staphylococcus aureus while delivering doxycycline to treat deep cystic acne lesions.

Isolated porcine lactic acid bacterial strains exhibit antimicrobial activity against E. coli and S. enteritidis.

Vegetable-derived lipid composition positions palmitic acid at the sn-2 triglyceride backbone to promote beneficial gut flora development in infants.

Plant-expressed PlcC-NetB fusion proteins replace antibiotics to prevent necrotic enteritis while eliminating antibiotic resistance selection.

Sodium deoxycholate mediates hydrophobic tunicamycins in water, resolving the trade-off between antibacterial activity and toxic solvent requirements.

Adjusting vaborbactam and meropenem doses by creatinine clearance prevents drug accumulation while preserving antibacterial efficacy against resistant strains.

Meta and para phenyl substituents on pleuromutilin derivatives boost antimicrobial activity against clinical pathogens like Staphylococcus aureus.

Multi-component plant extract combats fungal resistance by combining distinct mechanisms to clear skin infections without high-dose toxicity.

Chimeric polypeptides combine tail-associated murein-degrading enzymes with cell wall binding domains to degrade bacterial structures.

Conjugating MOMP VS4 antigen to anti-CD40 antibodies directs delivery to antigen presenting cells for enhanced immune response.

Nucant and GAG microspheres target nucleolin to reduce tumour growth while lowering side effects.

PA1Φ phage destroys target bacteria via self-replication while preserving normal flora, avoiding antibiotic resistance.

Formula I compounds inhibit coagulation factor IXa, reducing thrombosis risk while expanding therapeutic options for hemophilia B.

N-hydroxyformamide derivatives inhibit ADAM17 and ADAM10 to treat inflammatory disorders and cancer progression.

Antioxidant-coated silica gel reduces toxic nitrogen dioxide to therapeutic nitric oxide without high temperatures or complex catalysts.

Novel polycyclic urea compounds inhibit bacterial DNA gyrase and topoisomerase IV enzymes to disrupt replication.

Monoclonal antibodies bind specific epitopes on YKL-40 to block its biological function, inhibiting cell growth and inducing apoptosis in cancer cells.

Novel bicyclic compounds with specific nitrogen substitutions combat pathogenic bacteria resistance.

Segmented nucleic acid complexes with asymmetric duplex formations prevent signal leak and toxicity while maintaining high translation yield.

Combining xylanase with Bacillus strains stabilizes efficacy against inconsistent results from costly, unstable alternatives after antibiotic removal.

Amorphous silver compositions stabilize metallic nanoparticles to extend antimicrobial duration and resist light-induced discoloration.

A bacterial saccharide conjugation process uses controlled periodate oxidation to activate polysaccharides for carrier protein attachment.

Quinoline compounds deplete cellular ATP via enzyme inhibition to treat resistant infections.

Ring-closing metathesis cross-links stabilize stitched polypeptides against proteolytic degradation while preserving biological activity.

Bridged macrocycle derivatives form stable metal complexes to inhibit fungal pathogens, reducing drug toxicity in Cryptococcal meningitis treatments.

Novel compounds inhibit metallo-β-lactamases to protect carbapenem antibiotics from enzymatic degradation.

Formula I compounds block bacterial efflux pumps, lowering the minimum inhibitory concentration required to treat infections caused by resistant strains.

Engineered chimeric peptides overcome limited epitope universality by binding diverse HLA-DR molecules.

Novel chimeric JNK inhibitor peptides combine L- and D-amino acid sequences to resist proteolytic degradation while maintaining inhibitory potency.

Soluplus polymeric micelles encapsulate poorly soluble chain-like drugs within hydrophobic cores to increase aqueous solubility.

Oral beta-lactamase inhibitor compounds treat resistant bacterial infections by inhibiting Class A, C, and D enzymes to allow earlier patient discharge.

Oral or intrapulmonary human beta-defensin 2 normalizes immune responses by targeting pro-inflammatory cytokine pathways.

Macrocyclic peptides replace monoclonal antibodies to block PD-L1 interactions, resolving accessibility and specificity limitations in cancer therapy.

Formula I heterocyclic compounds antagonize the P2X7 receptor to treat chronic pain and inflammatory disorders.

Selective CD4 depletion prevents graft-versus-host disease while maintaining the graft-versus-tumor effect.

Mastic resin oral composition eliminates periodontal bacteria in pets, replacing mechanical brushing with a safe, economical chemical solution.

Bac-FRP-3 phages lyse resistant bacteria without harming commensal flora, bypassing antibiotic resistance.

Selective bicyclic heteroaryl inhibitors block leukotriene B4 production via targeted LTA4H modulation, avoiding corticosteroid side effects.

Lactobacillus rhamnosus CCFM1119 inhibits Helicobacter pylori via competitive binding, avoiding antibiotic resistance and adverse reactions.

Crystalline tazobactam arginine polymorphs enhance chemical stability and reduce hygroscopicity, lowering impurity levels in ceftolozane compositions.

Pyridazine-based pyridine derivatives inhibit COX-2 while minimizing gastric ulceration risks associated with traditional NSAIDs.

A polymyxin pharmaceutical composition uses a supramolecular derivative to lower binding affinity.

Modified lysins degrade peptidoglycan to kill resistant Pseudomonas aeruginosa and disrupt protective biofilms.

Triazolylphenyl sulfonamides resolve the potency-selectivity trade-off in B-RAF V600E inhibition by locking cancer cells in the G1 phase.

Laser treatment enhances bioavailability and antimicrobial efficacy against multi-drug resistant bacteria without complex extraction.

Lytic bacteriophages bind bacterial efflux pumps to increase antibiotic sensitivity, overcoming resistance in Pseudomonas aeruginosa biofilm infections.